Home

Research Interests

Lab Members

Publications

Current Publications  

Lab News

Past Lab Members

VBT Program

BBS Program

Department  of Pharmacology

 

 

 

           

 

Current

Publications

 

1.       Sessa WC(2004). "Atheroprotection in the abence of "caves": is it the fat, thevessels, or both?" Arterioscler Thromb Vasc Biol24(1): 4-6.

2.       Papapetropoulos A, Fulton D,  Lin MI, Fontana J, McCabe TJ,Zoellner S, Garcia-Cardena G, Zhou Z, Gratton JP  and Sessa WC. (2004). "Vanadate is a potent activator of endothelial nitric-oxide synthase: evidence for the role of the serine/threonine kinase Akt and the 90-kDa heat shock protein." Mol Pharmacol65(2): 407-15.

3.       Acevedo L,  Yu J, Erdjument-Bromage H, Miao RQ, Kim JE,Fulton D, Tempst P,. Strittmatter SM and Sessa WC. (2004). "A new role for Nogo as a regulator of vascular remodeling." Nat Med10(4): 382-8.

4.       Sessa WC. (2004). "eNOS at a glance." J Cell Sci117(Pt12): 2427-9.

5.       Gratton JP, Bernatchez P and Sessa WC. (2004). "Caveolaeand caveolins in the cardiovascular system." Circ Res94(11): 1408-17.

6.       Fulton, D, Babbitt R, Zoellner S, Fontana J, Acevedo L,McCabe TJ, Iwakiri Y and Sessa WC. (2004). "Targeting of endothelial nitric-oxide synthase to the cytoplasmic face of the Golgi complex or plasma membrane regulates Akt- versus calcium-dependent mechanisms for nitric oxide release." J Biol Chem279(29): 30349-57.

7.       Koh, KP, Wang Y, Yi T, Shiao SL, Lorber MI, Sessa WC,Tellides G and Pober J. (2004). "T cell-mediated vascular dysfunction of human allografts results from IFN-gamma dysregulation of NO synthase." J Clin Invest114(6): 846-56.

8.       Lin, MI and Sessa WC (2004). "Antiangiogenic therapy:creating a unique "window" of opportunity." Cancer Cell6(6): 529-31.

9.        Bauer PM, Yu J, Chen Y, Hickey R, Bernatchez PN, Looft-Wilson R, Huang Y, Giordano F, Stan RV and Sessa WC (2005). "Endothelial-specific expression of caveolin-1 impairs microvascular permeability and angiogenesis." Proc Natl Acad Sci U S A102(1): 204-9.

10. Bernatchez PN, Bauer PM, Prendergast JS, He P andSessaWC. (2005). "Dissecting the molecular control of endothelial NO synthase by caveolin-1 using cell-permeable peptides." Proc Natl Acad Sci U S A102(3): 761-6.

11. Bucci M., Roviezzo F, Posadas I, Yu J, Parente L, andSessaWC. (2005). "Endothelial nitric oxide synthase activation is critical for vascular leakage during acute inflammation in vivo." Proc Natl Acad Sci U S A102(3): 904-8.

11. Ackah E, Yu J, Zoellner S, Iwakiri Y, Skurk C, Shibata R, Ouchi N, Easton RM, Galasso G, Birnbaum MJ, Walsh K, Sessa WC. 2005. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest 115: 2119-2127.

12.  Yu J, Demuinck ED, Zhuang Z, Drinane M, Kauser K, Rubanyi GM, Qian HS, Murata T, Escalante B, Sessa WC. 2005. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci U S A 102: 10999-11004.

13.  Sessa WC. 2005. Regulation of endothelial derived nitric oxide in health and disease. Mem Inst Oswaldo Cruz 100 Suppl 1: 15-18.

14.  Zhang R, Luo D, Miao R, Bai L, Ge Q, Sessa WC, Min W. 2005. Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 24: 3954-3963.